Market Spotlight: Fibromyalgia
Market Spotlight: Fibromyalgia
$1,318.00
This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, patent information, and prevalence data, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, patent information, and prevalence data, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- The approved drugs in the fibromyalgia space target dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, serotonin reuptake, and voltage-gated calcium channels. All of the marketed drugs for fibromyalgia are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for fibromyalgia are in Phase II, with two drugs in Phase III.
- Therapies in development for fibromyalgia focus on a wide variety of targets. These drugs are most commonly administered via the oral route.
- The only high-impact upcoming event in the fibromyalgia space is topline Phase IIa trial results for ASP0819. The overall likelihood of approval of a Phase I pain asset is 7.2%, and the average probability a drug advances from Phase III is 58.6%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 9.8 years in the overall neurology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for fibromyalgia have been in the late phases of development, with 68% of trials in Phase III–IV, and 32% in Phase I–II.
- The US has a substantial lead in the number of fibromyalgia clinical trials globally. Germany, Spain, and the UK lead the major EU markets, while India has the top spot in Asia.
- Clinical trial activity in the fibromyalgia space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for fibromyalgia, with 23 trials.
- Pfizer leads industry sponsors with the highest overall number of clinical trials for fibromyalgia, followed by Allergan.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Symptoms
8 Patient subtypes
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Pharmacologic therapies
13 EPIDEMIOLOGY
13 Fibromyalgia prevalence
14 MARKETED DRUGS
16 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 Multiple Drugs for Fibromyalgia (June 25, 2019)
22 NYX-2925 for Fibromyalgia (June 10, 2019)
24 NYX-2925 for Fibromyalgia (December 3, 2018)
27 KEY UPCOMING EVENTS
28 PROBABILITY OF SUCCESS
29 LICENSING AND ASSET ACQUISITION DEALS
29 Axsome Gets Reboxetine Rights In Narcolepsy From Pfizer
31 PARENT PATENTS
32 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
37 BIBLIOGRAPHY
37 Prescription information
39 APPENDIX
LIST OF FIGURES
16 Figure 1: Overview of pipeline drugs for fibromyalgia in the US
17 Figure 2: Pipeline drugs for fibromyalgia, by company
17 Figure 3: Pipeline drugs for fibromyalgia, by drug type
17 Figure 4: Pipeline drugs for fibromyalgia, by classification
24 Figure 5: NYX-2925 for Fibromyalgia (June 10, 2019): Phase II – Pilot Study
26 Figure 6: NYX-2925 for Fibromyalgia (December 3, 2018): Phase II – Pilot Study
27 Figure 7: Key upcoming events in fibromyalgia
28 Figure 8: Probability of success in the fibromyalgia pipeline
29 Figure 9: Licensing and asset acquisition deals in fibromyalgia, 2015–20
31 Figure 10: Parent patents in fibromyalgia
33 Figure 11: Clinical trials in fibromyalgia
33 Figure 12: Top 10 drugs for clinical trials in fibromyalgia
34 Figure 13: Top 10 companies for clinical trials in fibromyalgia
34 Figure 14: Trial locations in fibromyalgia
35 Figure 15: Fibromyalgia trials status
36 Figure 16: Fibromyalgia trials sponsors, by phase
LIST OF TABLES
15 Table 1: Marketed drugs for fibromyalgia
19 Table 2: Pipeline drugs for fibromyalgia in the US
22 Table 3: Multiple Drugs for Fibromyalgia (June 25, 2019)
23 Table 4: NYX-2925 for Fibromyalgia (June 10, 2019)
25 Table 5: NYX-2925 for Fibromyalgia (December 3, 2018)
32 Table 6: Historical global sales, by drug ($m), 2014–18
32 Table 7: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the